Skip to main content
Premium Trial:

Request an Annual Quote

Invitae, PCT Therapeutics, Genome Medical Partner to Offer Genetic Testing for Cerebral Palsy

NEW YORK – PTC Therapeutics, Genome Medical, and Invitae are partnering to offer genetic testing free of charge to patients in the US who have symptoms or a diagnosis of cerebral palsy with no evidence of brain injury, PTC said on Wednesday.

The initiative, called PTC Pinpoint Direct-CP Spectrum, is a genetic testing program that includes genetic counseling for eligible patients. Genome Medical will provide the counseling and administration and Invitae the genetic testing. The partners are hoping that testing through PTC Pinpoint Direct-CP Spectrum may help uncover a genetic cause for each person's symptoms and determine the right plan for the patient's care, including new and emerging treatment options. PTC focuses on developing new therapies for patients with rare disorders.

The company noted that this is an extension of an existing program, PTC Pinpoint, and that it is designed to further eliminate barriers of genetic testing for rare diseases.

"An umbrella diagnosis of a neurotransmitter disorder, such as cerebral palsy, can be extremely frustrating, especially for patients and caregivers who spend years with unexplained and underlying symptoms," Kylie O'Keefe, senior VP of global commercial and corporate strategy for PTC, said in a statement. "Up to one-third of cerebral palsy cases are driven by a genetic disorder, and some of those conditions may have transformative treatments currently available."

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.